Pharnext closes €4.8-million Series A funding round

Published June 13, 2010

Pharnext closes €4.8-million Series A funding round
Pharnext SAS, a biopharmaceutical company specializing in the development of innovative treatments based on Pleotherapy™ for severe neurological diseases, today announced that it had closed a €4.8-million Series A round of funding on June 3rd (corresponding to a company valuation of €45 million).